Large And Small-Scale Bioprocessing Global Market Report 2024

The large and small-scale bioprocessing market size has grown rapidly in recent years. It will grow from $52.59 billion in 2023 to $59.63 billion in 2024 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to regulatory standards, medical industry growth, technological advancements, pharmaceutical and biotechnology investments, and food safety concerns.

The large and small-scale bioprocessing market size is expected to see rapid growth in the next few years. It will grow to $99.03 billion in 2028 at a compound annual growth rate (CAGR) of 13.5%. The anticipated growth during the forecast period is influenced by several factors, including the rise in healthcare spending, the expansion of the pharmaceutical and biotechnology industries, technological advancements, regulatory pressures, heightened awareness of food safety, and the repercussions of the COVID-19 pandemic. Key trends expected in this period encompass the adoption of advanced technologies, geographical expansion, the outsourcing of sterilization services, the promotion of sustainable practices, the development of hybrid sterilization techniques, and the provision of customized sterilization solutions.

The increasing demand for biologics is poised to drive the expansion of the large and small-scale bioprocessing market in the future. Biologics encompass medicinal products derived from living organisms or their components, including vaccines, blood and blood components, gene therapies, tissues, and recombinant therapeutic proteins. The escalating demand for biologics is attributed to advancements in biotechnology, enhanced understanding of disease mechanisms, and the desire for targeted and personalized therapies. Both large-scale and small-scale bioprocessing play vital roles in the successful development and commercialization of biologics. Small-scale bioprocessing is crucial for early-stage development, optimization, and feasibility studies, whereas large-scale bioprocessing ensures efficient, consistent, and regulatory-compliant production of biologics for commercial distribution. For instance, in February 2024, according to the National Library of Medicine, a US-based medical library, the Food and Drug Administration (FDA) approved 55 new drugs in 2023, including 29 new chemical entities (NCEs) and 25 new biological entities (NBEs), marking a 50% increase compared to the 37 approvals in 2022. Hence, the growing demand for biologics is a driving force behind the growth of the large and small-scale bioprocessing market.

Key players in the large and small-scale bioprocessing market are innovating their product offerings, such as introducing single-use centrifuge systems, to provide customers with enhanced features. Single-use centrifuge systems are disposable and pre-sterilized devices designed for the separation of biological materials in bioprocessing. For instance, in September 2022, Thermo Fisher Scientific Inc., a US-based biotechnology company, unveiled the DynaSpin Single-Use Centrifuge system. This system aims to enhance large-scale cell culture harvesting by simplifying the separation process, reducing the need for depth filtration cartridges, and delivering advantages such as improved product yield, operational efficiency, cost savings, and sustainable practices in biologics production. The DynaSpin system contributes to cost reduction in production and supports sustainability objectives by significantly reducing material usage and waste compared to traditional harvest systems.

In December 2022, Merck KGaA, a German science and technology company, purchased Erbi Biosystems for an undisclosed sum. This acquisition bolsters Merck's portfolio in upstream therapeutic proteins, facilitating scalable cell-based perfusion bioreactor processes spanning from 2 milliliters (mL) to 2000 liters (L). Erbi Biosystems, based in the US, offers a range of bioprocessing solutions catering to both large and small-scale applications.

Major companies operating in the large and small-scale bioprocessing market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, 3M Company, Takeda Pharmaceutical Company Ltd., Danaher Corporation, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Becton Dickinson and Company (BD), Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY LIMITED, Lonza Group, Sun Pharmaceutical Industries Ltd., GE Healthcare Life Sciences, Sartorius AG, Dr. Reddy's Laboratories Ltd., Alkem Laboratories Limited, Piramal Enterprises Ltd.

North America was the largest region in the large and small-scale bioprocessing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the large and small-scale bioprocessing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the large and small-scale bioprocessing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Large and small-scale bioprocessing are critical facets of the biotechnology and pharmaceutical sectors, employing living cells or their components to produce desired outputs such as pharmaceuticals, chemicals, and biofuels. Large-scale bioprocessing denotes the industrial-level manufacturing of biological products, utilizing large bioreactors and substantial infrastructure. Conversely, small-scale bioprocessing entails the production of biological products on a smaller scale, often for research, development, pilot studies, or specialized markets.

The primary products of both large and small-scale bioprocessing encompass bioreactors or fermenters, cell culture items, filtration assemblies, bioreactor accessories, bags, containers, and others. Bioreactors, also known as fermenters, are vessels engineered to facilitate the growth and metabolic processes of microorganisms or cells under controlled conditions to yield desired biological outputs. They are utilized through various modalities, including in-house and outsourced, and cater to several workflows, predominantly downstream processing, fermentation, and upstream processing. These products find application across a range of scales, from industrial to small-scale, and are employed in diverse sectors such as biopharmaceuticals, specialty industrial chemicals, and environmental aids.

The large and small-scale bioprocessing market research report is one of a series of new reports that provides large and small-scale bioprocessing market statistics, including large and small-scale bioprocessing industry global market size, regional shares, competitors with a large and small-scale bioprocessing market share, detailed large and small-scale bioprocessing market segments, market trends and opportunities, and any further data you may need to thrive in the large and small-scale bioprocessing industry. This large and small-scale bioprocessing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The large and small-scale bioprocessing market consists of revenues earned by entities by providing plant cell bioprocessing, microbial bioprocessing, animal cell bioprocessing, and algal bioprocessing. The market value includes the value of related goods sold by the service provider or included within the service offering. The large and small-scale bioprocessing market also includes sales of shakers, incubators, and cell culture media. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.